Home › Funds › ORBIMED ADVISORS LLC › SNDX

ORBIMED ADVISORS LLC position in SNDX

SYNDAX PHARMACEUTICALS INC · Health Care

ORBIMED ADVISORS LLC reported holding 1,542,000 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$33.7M, representing 0.68% of its reported portfolio and ranking #39 among its reported holdings. ORBIMED ADVISORS LLC has disclosed SNDX holdings in 7 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.54M sh
Reported value held$33.71M
Portfolio Weight0.68%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ORBIMED ADVISORS LLC's SNDX position evolved

ORBIMED ADVISORS LLC first disclosed a stake in SNDX in Q3 2023 at 1,284,000 shares (US$18.6M). The position peaked in Q1 2024 at 1,749,000 shares, worth US$41.6M. Across 7 filings, ORBIMED ADVISORS LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,542,000 shares valued at US$33.7M — an increase of 579,700 shares quarter over quarter.. Notable position changes include a 36% increase in Q4 2023 (shares rose 10% over the following quarter), a 60% increase in Q2 2026 (shares fell 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.28M $18.64M New
Q4 2023 1.75M $37.80M Add
Q1 2024 1.75M $41.63M Hold
Q2 2024 1.93M $39.53M Add
Q3 2024 1.93M $37.06M Hold
Q1 2026 962.30K $22.48M New
Q2 2026 1.54M $33.71M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SNDX and 13F data

SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 42 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SNDX

All SNDX fund holders →

FAQ

How long has ORBIMED ADVISORS LLC held SNDX?

ORBIMED ADVISORS LLC has disclosed SNDX holdings in 7 of the last 12 reported quarters, going back to Q3 2023.

What is ORBIMED ADVISORS LLC's current position in SNDX?

As of Q2 2026, ORBIMED ADVISORS LLC holds 1.54M shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $33.71M, representing 0.68% of its reported portfolio and ranking #39.

Has ORBIMED ADVISORS LLC been buying or selling SNDX?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in SNDX. The position peaked in Q1 2024 at 1.75M shares.

Which other funds hold SNDX?

Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.